GLUE (Monte Rosa Therapeutics) OCF Margin %: -887.62% (As of Mar. 2026)

What is Monte Rosa Therapeutics OCF Margin %?

Monte Rosa Therapeutics GLUE -7.38% 34 OCF Margin % is -887.62% as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 950 Biotechnology companies, Monte Rosa Therapeutics ranks better than 55.37% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Monte Rosa Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-37.37 Mil. Monte Rosa Therapeutics's Revenue for the three months ended in Mar. 2026 was $4.21 Mil. Therefore, Monte Rosa Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was -887.62%.

As of today, Monte Rosa Therapeutics's current OCF Yield % is -0.81%.

The historical rank and industry rank for Monte Rosa Therapeutics's OCF Margin % or its related term are showing as below:

GLUE' s OCF Margin % Range Over the Past 10 Years
Min: -18.43 Med: 18.55 Max: 55.53
Current: -34.17

During the past 7 years, the highest OCF Margin % of Monte Rosa Therapeutics was 55.53%. The lowest was -18.43%. And the median was 18.55%.

GLUE's OCF Margin % is ranked better than
55.37% of 950 companies
in the Biotechnology industry
Industry Median: -65.71 vs GLUE: -34.17

Monte Rosa Therapeutics OCF Margin % Related Terms

Monte Rosa Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics OCF Margin % Chart

Monte Rosa Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

0.00

55.53

-18.43

Monte Rosa Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-53.56	-149.69	786.56	-1,546.71	-887.62

GLUE vs SNDX, IOVA, TYRA: OCF Margin % Comparison

For the Biotechnology subindustry, Monte Rosa Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's OCF Margin % falls into.

Save Embed

34GF Score

Monte Rosa Therapeutics Inc GLUE

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Monte Rosa Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Monte Rosa Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-22.798	/	123.672
	=	-18.43 %

Monte Rosa Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-37.369	/	4.21
	=	-887.62 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -887.62% mean?

Monte Rosa Therapeutics (GLUE) has a OCF Margin % of -887.62% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Monte Rosa Therapeutics and its competitors. According to the industry distribution chart, Monte Rosa Therapeutics ranks #424 out of 950 companies in the Biotechnology industry, placing it in the top 44.6%.

Is Monte Rosa Therapeutics' OCF Margin % too high?

Monte Rosa Therapeutics' current OCF Margin % is -887.62%. Based on the distribution chart, Monte Rosa Therapeutics ranks #424 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does Monte Rosa Therapeutics' OCF Margin % compare to SNDX and IOVA?

According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #424 out of 950 companies for OCF Margin %. This puts Monte Rosa Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current OCF Margin % is -887.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Monte Rosa Therapeutics stock overvalued right now?

Monte Rosa Therapeutics (GLUE) has a current OCF Margin % of -887.62%. The current OCF Margin % is -887.62%. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current OCF Margin % is -887.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SNDX IOVA TYRA RXRX SION RAPP ABSI ANAB GHRS TSHA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118

Website https://www.monterosatx.com

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

34GF Score

Get the complete analysis for GLUE

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.32

Price

View GLUE Analysis

See OCF Margin % data for all stocks →